Search research articles
Contact Us
Filters
Showing results (11-20 of 430) with videos related to
Page
of 43
Sort By:
Leukemia & Lymphoma
|
November 4, 2020
How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
R Andrew Harkins, Christopher R Flowers
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 1, 2018
Balancing patient value and payer cost in hematologic malignancies: can it be done?
Pamela B Allen, Christopher R Flowers
JAMA Network Open
|
January 16, 2019
Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer
Lauren E McCullough, Christopher R Flowers
Oncology (Williston Park, N.Y.)
|
July 17, 2015
A Plethora of Novel Therapies--Which One to Choose?
Jonathon B Cohen, Christopher R Flowers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2018
What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
Christopher R Flowers, Scott D Ramsey
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A decade of progress in lymphoma: advances and continuing challenges
Christopher R Flowers, James O Armitage
Blood
|
January 9, 2016
Identifying risk factors for B-cell lymphoma
Christopher R Flowers, Christine F Skibola
Cancer
|
May 3, 2017
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Jean L Koff, Christopher R Flowers
Hematology. American Society of Hematology. Education Program
|
February 20, 2015
Optimal disease surveillance strategies in non-Hodgkin lymphoma
Jonathon B Cohen, Christopher R Flowers
Community Oncology
|
January 15, 2013
Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice
Loretta J Nastoupil, Christopher R Flowers
Page
of 43
Search research articles
Search
Showing results (11-20 of 430) with videos related to
Sort By:
Page
of 43
Leukemia & Lymphoma
|
November 4, 2020
How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
R Andrew Harkins, Christopher R Flowers
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 1, 2018
Balancing patient value and payer cost in hematologic malignancies: can it be done?
Pamela B Allen, Christopher R Flowers
JAMA Network Open
|
January 16, 2019
Identifying and Addressing Disparities in Survival Outcomes for Rural Patients With Cancer
Lauren E McCullough, Christopher R Flowers
Oncology (Williston Park, N.Y.)
|
July 17, 2015
A Plethora of Novel Therapies--Which One to Choose?
Jonathon B Cohen, Christopher R Flowers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2018
What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
Christopher R Flowers, Scott D Ramsey
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A decade of progress in lymphoma: advances and continuing challenges
Christopher R Flowers, James O Armitage
Blood
|
January 9, 2016
Identifying risk factors for B-cell lymphoma
Christopher R Flowers, Christine F Skibola
Cancer
|
May 3, 2017
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Jean L Koff, Christopher R Flowers
Hematology. American Society of Hematology. Education Program
|
February 20, 2015
Optimal disease surveillance strategies in non-Hodgkin lymphoma
Jonathon B Cohen, Christopher R Flowers
Community Oncology
|
January 15, 2013
Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice
Loretta J Nastoupil, Christopher R Flowers
Page
of 43